TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Hansa Biopharma AB ( (SE:HNSA) ) has issued an announcement.
Hansa Biopharma AB announced its intention to raise approximately USD 60 million through a directed share issue aimed at Swedish and international institutional investors. The funds will support the company’s strategic initiatives, including the potential filing of a Biologic License Application with the FDA and preparations for the commercial launch of imlifidase in the U.S. The decision for a directed share issue, as opposed to a rights issue, was made to ensure timely capital acquisition and to attract strategic biotechnology investors, reflecting the company’s proactive approach to strengthening its market position.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a biopharmaceutical company based in Lund, Sweden, specializing in the development of novel immunomodulatory treatments. The company focuses on addressing rare diseases and conditions such as kidney transplants and autoimmune diseases, with a significant market focus on the United States.
Average Trading Volume: 524,776
Technical Sentiment Signal: Buy
Current Market Cap: SEK3.3B
See more insights into HNSA stock on TipRanks’ Stock Analysis page.